Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Halictus rubicundus genome sequencing

PROVIDER: PRJNA1146431 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30145932_1.fastq.gz	Fastqsanger.gz
	SRR30145932_2.fastq.gz	Fastqsanger.gz
	SRR30145933_1.fastq.gz	Fastqsanger.gz
	SRR30145933_2.fastq.gz	Fastqsanger.gz
	SRR30145934_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

Halictus rubicundus

Project description:Halictus rubicundus overview

| PRJNA1267242 | ENA

Halictus rubicundus

Project description:Halictus rubicundus alternate haplotype genome sequencing

| PRJNA1144826 | ENA

Halictus rubicundus

Project description:Halictus rubicundus principal haplotype genome sequencing

| PRJNA1144827 | ENA

Project description:Transcriptome sequence data of eusocial and solitary populations of Halictus rubicundus

| PRJNA980229 | ENA

Halobellus rubicundus strain:MBLA0158

Project description:Halobellus rubicundus strain:MBLA0158 Genome sequencing

| PRJNA904033 | ENA

Haloplanus rubicundus strain:CBA1112

Project description:Haloplanus rubicundus strain:CBA1112 Genome sequencing

| PRJNA481590 | ENA

Haloplanus rubicundus strain:CBA1113

Project description:Haloplanus rubicundus strain:CBA1113 Genome sequencing

| PRJNA481607 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc